tetano
Editor, Senior Moderator
Curr Probl Cardiol
. 2022 Dec 14;101553.
doi: 10.1016/j.cpcardiol.2022.101553. Online ahead of print.
Impact of COVID-19 on Patients Hospitalized with Deep Vein Thrombosis and/or Pulmonary Embolism: A Nationwide Analysis
Adrija Hajra[SUP] 1 [/SUP], Akshay Goel[SUP] 2 [/SUP], Aaqib H Malik[SUP] 2 [/SUP], Ameesh Isath[SUP] 2 [/SUP], Rishi Shrivastav[SUP] 3 [/SUP], Rahul Gupta[SUP] 4 [/SUP], Subrat Das[SUP] 2 [/SUP], Chayakrit Krittanawong[SUP] 5 [/SUP], Dhrubajyoti Bandyopadhyay[SUP] 6 [/SUP]
Affiliations
Abstract
The Coronavirus disease 2019 (COVID-19) infection predisposes patients to develop deep vein thrombosis (DVT) and pulmonary embolism (PE). In this study, we compared the in-hospital outcomes of patients with DVT and/or PE with concurrent COVID-19 infection vs. those with concurrent flu infection. The National Inpatient Sample from 2019 to 2020 was analyzed to identify all adult admissions diagnosed with DVT and PE. These patients were then stratified based on whether they had concomitant COVID-19 or flu. We identified 62,895 hospitalizations with the diagnosis of DVT and/or PE with concomitant COVID-19, and 8,155 hospitalizations with DVT and/or PE with concomitant flu infection. After 1:1 propensity score match, the incidence of cardiac arrest and inpatient mortality were higher in the COVID-19 group. The incidence of cardiogenic shock was higher in the flu group. Increased age, Hispanic race, diabetes, chronic kidney disease, arrhythmia, liver disease, coagulopathy, and rheumatologic diseases were the independent predictors of mortality in patients with DVT and/or PE with concomitant COVID-19.
Keywords: Coronavirus disease 2019 (COVID-19); National Inpatient Sample; deep vein thrombosis; pulmonary embolism.
. 2022 Dec 14;101553.
doi: 10.1016/j.cpcardiol.2022.101553. Online ahead of print.
Impact of COVID-19 on Patients Hospitalized with Deep Vein Thrombosis and/or Pulmonary Embolism: A Nationwide Analysis
Adrija Hajra[SUP] 1 [/SUP], Akshay Goel[SUP] 2 [/SUP], Aaqib H Malik[SUP] 2 [/SUP], Ameesh Isath[SUP] 2 [/SUP], Rishi Shrivastav[SUP] 3 [/SUP], Rahul Gupta[SUP] 4 [/SUP], Subrat Das[SUP] 2 [/SUP], Chayakrit Krittanawong[SUP] 5 [/SUP], Dhrubajyoti Bandyopadhyay[SUP] 6 [/SUP]
Affiliations
- PMID: 36528208
- DOI: 10.1016/j.cpcardiol.2022.101553
Abstract
The Coronavirus disease 2019 (COVID-19) infection predisposes patients to develop deep vein thrombosis (DVT) and pulmonary embolism (PE). In this study, we compared the in-hospital outcomes of patients with DVT and/or PE with concurrent COVID-19 infection vs. those with concurrent flu infection. The National Inpatient Sample from 2019 to 2020 was analyzed to identify all adult admissions diagnosed with DVT and PE. These patients were then stratified based on whether they had concomitant COVID-19 or flu. We identified 62,895 hospitalizations with the diagnosis of DVT and/or PE with concomitant COVID-19, and 8,155 hospitalizations with DVT and/or PE with concomitant flu infection. After 1:1 propensity score match, the incidence of cardiac arrest and inpatient mortality were higher in the COVID-19 group. The incidence of cardiogenic shock was higher in the flu group. Increased age, Hispanic race, diabetes, chronic kidney disease, arrhythmia, liver disease, coagulopathy, and rheumatologic diseases were the independent predictors of mortality in patients with DVT and/or PE with concomitant COVID-19.
Keywords: Coronavirus disease 2019 (COVID-19); National Inpatient Sample; deep vein thrombosis; pulmonary embolism.